ACRO BIOMEDICAL CO., LTD.

2023 Q2 Form 10-Q Financial Statement

#000164033423001563 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.680K $12.11K
YoY Change -77.87% -94.38%
Cash & Equivalents $2.680K $12.11K
Short-Term Investments
Other Short-Term Assets $24.98K $20.30K
YoY Change 23.05% -16.8%
Inventory $296.0K
Prepaid Expenses $8.750K $8.295K
Receivables $498.5K $298.5K
Other Receivables $0.00 $0.00
Total Short-Term Assets $526.2K $626.9K
YoY Change -16.07% -8.87%
LONG-TERM ASSETS
Property, Plant & Equipment $12.99K $38.20K
YoY Change -65.99% 206.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $4.230K
YoY Change -100.0%
Total Long-Term Assets $12.99K $42.43K
YoY Change -69.39% 240.14%
TOTAL ASSETS
Total Short-Term Assets $526.2K $626.9K
Total Long-Term Assets $12.99K $42.43K
Total Assets $539.1K $669.3K
YoY Change -19.45% -4.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $87.54K $15.00K
YoY Change 483.6% 24.28%
Accrued Expenses $12.99K $25.21K
YoY Change -48.47% 107.49%
Deferred Revenue
YoY Change
Short-Term Debt $78.97K $21.25K
YoY Change 271.62% 33.4%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $199.5K $81.46K
YoY Change 144.91% 35.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $12.99K
YoY Change
Total Long-Term Liabilities $0.00 $12.99K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $199.5K $81.46K
Total Long-Term Liabilities $0.00 $12.99K
Total Liabilities $199.5K $94.44K
YoY Change 111.23% 56.99%
SHAREHOLDERS EQUITY
Retained Earnings -$31.01M -$15.86M
YoY Change 95.49% 1351.45%
Common Stock $60.04K $60.04K
YoY Change 0.0% -99.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $339.7K $574.9K
YoY Change
Total Liabilities & Shareholders Equity $539.1K $669.3K
YoY Change -19.45% -4.43%

Cashflow Statement

Concept 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1185 usd
acbm Imputed Interest Related Parties
ImputedInterestRelatedParties
1577 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-296000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
498500 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
638500 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12988 usd
CY2023Q2 us-gaap Assets
Assets
539148 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
87536 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
76571 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12988 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25719 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
222000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
76500 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1316425 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2799991 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2961520 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1878275 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2520000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4398275 usd
CY2023Q2 us-gaap Other Expenses
OtherExpenses
789 usd
CY2022Q2 us-gaap Other Expenses
OtherExpenses
211 usd
us-gaap Other Expenses
OtherExpenses
1577 usd
us-gaap Other Expenses
OtherExpenses
420 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3195489 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3996643 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7199843 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7925440 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8750 usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
dei Entity Address City Or Town
EntityAddressCityOrTown
Fishers
dei Entity Address State Or Province
EntityAddressStateOrProvince
IN
us-gaap Operating Lease Expense
OperatingLeaseExpense
13140 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55643
dei Entity Registrant Name
EntityRegistrantName
ACRO BIOMEDICAL CO., LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1950356
dei Entity Address Address Line1
EntityAddressAddressLine1
12175 Visionary Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1160
dei Entity Central Index Key
EntityCentralIndexKey
0001622996
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60042000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60042000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60042000 shares
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
46038
dei City Area Code
CityAreaCode
317
dei Local Phone Number
LocalPhoneNumber
286-6788
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60042000 shares
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2680 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5852 usd
CY2023Q2 acbm Purchase Deposit For Inventory Current
PurchaseDepositForInventoryCurrent
12000 usd
CY2022Q4 acbm Purchase Deposit For Inventory Current
PurchaseDepositForInventoryCurrent
12000 usd
CY2023Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
4230 usd
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
0 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
526160 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
657537 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25719 usd
CY2023Q2 us-gaap Security Deposit
SecurityDeposit
0 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
4230 usd
CY2022Q4 us-gaap Assets
Assets
687486 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78970 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78826 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
199494 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
201116 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60042000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
60042 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
60042 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32296813 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32295236 usd
CY2023Q2 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
1009433 usd
CY2022Q4 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
8060983 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-31007768 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23807925 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
339654 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
486370 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
539148 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
687486 usd
CY2022Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
298500 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1476432 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5040000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
3194700 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
3996432 usd
us-gaap Operating Expenses
OperatingExpenses
7198266 usd
us-gaap Operating Expenses
OperatingExpenses
8001520 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3194700 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3996432 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7198266 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7925020 usd
CY2023Q2 acbm Interest Expenses Related Party
InterestExpensesRelatedParty
789 usd
CY2022Q2 acbm Interest Expenses Related Party
InterestExpensesRelatedParty
211 usd
acbm Interest Expenses Related Party
InterestExpensesRelatedParty
1577 usd
acbm Interest Expenses Related Party
InterestExpensesRelatedParty
420 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3195489 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3996643 usd
us-gaap Net Income Loss
NetIncomeLoss
-7199843 usd
us-gaap Net Income Loss
NetIncomeLoss
-7925440 usd
CY2023Q2 acbm Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.05
CY2022Q2 acbm Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.07
acbm Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.12
acbm Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.13
CY2023Q2 acbm Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
60042000 shares
CY2022Q2 acbm Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
60042000 shares
acbm Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
60042000 shares
acbm Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
60042000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
486370 usd
CY2023Q1 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
3928100 usd
CY2023Q1 acbm Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
788 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4004354 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
410904 usd
CY2023Q2 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
3123450 usd
CY2023Q2 acbm Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
789 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3195489 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
339654 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
643707 usd
CY2022Q1 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
3928100 usd
CY2022Q1 acbm Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
209 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3928797 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
643219 usd
CY2022Q2 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
3928100 usd
CY2022Q2 acbm Imputed Interest On Related Party Loans
ImputedInterestOnRelatedPartyLoans
211 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3996643 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
574887 usd
us-gaap Profit Loss
ProfitLoss
-7199843 usd
us-gaap Profit Loss
ProfitLoss
-7925440 usd
acbm Imputed Interest Related Parties
ImputedInterestRelatedParties
420 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
7051550 usd
us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
7856200 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
140000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
299500 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7565 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7128 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10965 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11197 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3316 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83645 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
144 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
504 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
504 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3172 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-83141 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5852 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95248 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2680 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12107 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
acbm Discription Of Contracts
DiscriptionOfContracts
the contracts with the consultants either expired in May 2023 or will expire in August 2023
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12988 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25719 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12988 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25719 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
13140 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13140 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
13140 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
13140 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6570 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
6570 usd
CY2023Q2 acbm Restricted Stock Grants Issued
RestrictedStockGrantsIssued
370000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7051550 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7856200 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3123450 usd
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
3928100 usd
CY2023Q2 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
1009433 usd
CY2022Q4 us-gaap Deferred Compensation Equity
DeferredCompensationEquity
8060983 usd

Files In Submission

Name View Source Status
0001640334-23-001563-index-headers.html Edgar Link pending
0001640334-23-001563-index.html Edgar Link pending
0001640334-23-001563.txt Edgar Link pending
0001640334-23-001563-xbrl.zip Edgar Link pending
acbm-20230630.xsd Edgar Link pending
acbm_10q.htm Edgar Link pending
acbm_ex311.htm Edgar Link pending
acbm_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acbm-20230630_def.xml Edgar Link unprocessable
acbm-20230630_pre.xml Edgar Link unprocessable
acbm-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acbm-20230630_cal.xml Edgar Link unprocessable
acbm_10q_htm.xml Edgar Link completed